<DOC>
	<DOCNO>NCT00310648</DOCNO>
	<brief_summary>Clinical Trial Two part : Part 1 : Phase I , Open-Label , Single-Center Study Evaluate Safety adjuvanted Influenza Vaccine When Administered Elderly Subjects . Part 2 : A Phase III , Randomized , Controlled , Observer-blind , Single-Center Study Evaluate Immunogenicity Safety adjuvanted conventional Influenza Vaccine When Administered Elderly Subjects .</brief_summary>
	<brief_title>Comparative Trial Evaluating Safety Immunogenicity Adjuvanted Conventional Influenza Vaccine Elderly Subjects ( &gt; 60 Years )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects 60 year age old , mentally competent , willing able give write informed consent prior study entry Any serious disease : cancer , autoimmune disease , advance arteriosclerotic disease complicate diabetes mellitus , chronic obstructive pulmonary disease ( COPD ) require oxygen therapy , acute progressive hepatic disease , acute progressive renal disease , congestive heart failure . Hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component vaccine . History neurological symptom sign , anaphylactic shock follow administration vaccine . Known suspected ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Influenza , elderly , vaccine</keyword>
</DOC>